Abstract
Purpose : To determine the diagnostic performance of mammoscintigraphy (SMG) with the 99m Tc-methoxy-isobutyl-isonitrile ( 99m Tc-MIBI) when used for assessment of the response to neoadjuvant chemotherapy (NACT) in patients with triple-negative and HER2-positive breast cancer (BC). Materials and methods : This retrospective study included 93 patients with morphologically verified triple-negative and HER2-positive breast cancer who received NACT between 2011 and 2018. Mammoscintigraphy was performed before treatment, after 2–3 and/or after 4–6 cycles of NACT. Diagnostic conclusions of SMG were compared with the results of morphological examination after surgical treatment at the end of NACT. The degree of pathological response to NACT was evaluated according to the Miller-Payne classification. Results : Overall, the sensitivity and specificity of SMG in predicting of complete pathologic tumor response after the completion of NACT were 83 % and 92 %, respectively. In patients with triple-negative and HER2-positive BC, sensitivity and specificity were 87 % and 92 %; 78 % and 91 %, respectively. When a complete scintigraphic response (grade V) was achieved after 2–3 cycles of NACT, the specificity and positive predictive value of SMG reached 100 % for both aggressive BC subtypes. Conclusions : The obtained results indicate the high diagnostic potential of SMG in predicting complete pathological tumor response to the NACT. Exceptional specificity and positive predictive value of SMG in the middle of the NACT make it promising tool in selection of BC patients for surgery de-escalation/elimination.

This publication has 20 references indexed in Scilit: